Vitro Diagnostics (OTCMKTS:VODG – Get Rating) and AVROBIO (NASDAQ:AVRO – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.
Insider & Institutional Ownership
55.7% of AVROBIO shares are owned by institutional investors. 27.7% of Vitro Diagnostics shares are owned by company insiders. Comparatively, 6.4% of AVROBIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Vitro Diagnostics and AVROBIO’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vitro Diagnostics | N/A | N/A | N/A |
| AVROBIO | N/A | -117.18% | -87.33% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Vitro Diagnostics and AVROBIO, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vitro Diagnostics | 0 | 0 | 0 | 0 | N/A |
| AVROBIO | 0 | 0 | 2 | 0 | 3.00 |
AVROBIO has a consensus target price of $5.00, suggesting a potential upside of 323.73%. Given AVROBIO’s higher possible upside, analysts clearly believe AVROBIO is more favorable than Vitro Diagnostics.
Earnings & Valuation
This table compares Vitro Diagnostics and AVROBIO’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vitro Diagnostics | $3.29 million | N/A | -$6.86 million | N/A | N/A |
| AVROBIO | N/A | N/A | -$105.89 million | ($2.30) | -0.51 |
Vitro Diagnostics has higher revenue and earnings than AVROBIO.
Summary
Vitro Diagnostics beats AVROBIO on 5 of the 8 factors compared between the two stocks.
About Vitro Diagnostics
(Get Rating)
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson’s, and Alzheimer’s diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.
About AVROBIO
(Get Rating)
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
Receive News & Ratings for Vitro Diagnostics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vitro Diagnostics and related companies with MarketBeat.com’s FREE daily email newsletter.